亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

易普利姆玛 医学 彭布罗利珠单抗 打开标签 内科学 肿瘤科 开放标签研究 癌症 临床试验 不利影响 免疫疗法
作者
Jacob Schachter,Antoni Ribas,Georgina V. Long,Ana Arance,Jean‐Jacques Grob,Laurent Mortier,Adil Daud,Matteo S. Carlino,Catriona M. McNeil,Michal Lotem,James Larkin,Paul Lorigan,Bart Neyns,Christian U. Blank,Teresa M. Petrella,Omid Hamid,Haiyu Zhou,Scot Ebbinghaus,Nageatte Ibrahim,Caroline Robert
出处
期刊:The Lancet [Elsevier BV]
卷期号:390 (10105): 1853-1862 被引量:1221
标识
DOI:10.1016/s0140-6736(17)31601-x
摘要

Summary

Background

Interim analyses of the phase 3 KEYNOTE-006 study showed superior overall and progression-free survival of pembrolizumab versus ipilimumab in patients with advanced melanoma. We present the final protocol-specified survival analysis.

Methods

In this multicentre, open-label, randomised, phase 3 trial, we recruited patients from 87 academic institutions, hospitals, and cancer centres in 16 countries (Australia, Austria, Belgium, Canada, Chile, Colombia, France, Germany, Israel, Netherlands, New Zealand, Norway, Spain, Sweden, UK, and USA). We randomly assigned participants (1:1:1) to one of two dose regimens of pembrolizumab, or one regimen of ipilimumab, using a centralised, computer-generated allocation schedule. Treatment assignments used blocked randomisation within strata. Eligible patients were at least 18 years old, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, at least one measurable lesion per Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST v1.1), unresectable stage III or IV melanoma (excluding ocular melanoma), and up to one previous systemic therapy (excluding anti-CTLA-4, PD-1, or PD-L1 agents). Secondary eligibility criteria are described later. Patients were excluded if they had active brain metastases or active autoimmune disease requiring systemic steroids. The primary outcome was overall survival (defined as the time from randomisation to death from any cause). Response was assessed per RECIST v1.1 by independent central review at week 12, then every 6 weeks up to week 48, and then every 12 weeks thereafter. Survival was assessed every 12 weeks, and final analysis occurred after all patients were followed up for at least 21 months. Primary analysis was done on the intention-to-treat population (all randomly assigned patients) and safety analyses were done in the treated population (all randomly assigned patients who received at least one dose of study treatment). Data cutoff date for this analysis was Dec 3, 2015. This study was registered with ClinicalTrials.gov, number NCT01866319.

Findings

Between Sept 18, 2013, and March 3, 2014, 834 patients with advanced melanoma were enrolled and randomly assigned to receive intravenous pembrolizumab every 2 weeks (n=279), intravenous pembrolizumab every 3 weeks (n=277), or intravenous ipilimumab every 3 weeks (ipilimumab for four doses; n=278). One patient in the pembrolizumab 2 week group and 22 patients in the ipilimumab group withdrew consent and did not receive treatment. A total of 811 patients received at least one dose of study treatment. Median follow-up was 22·9 months; 383 patients died. Median overall survival was not reached in either pembrolizumab group and was 16·0 months with ipilimumab (hazard ratio [HR] 0·68, 95% CI 0·53–0·87 for pembrolizumab every 2 weeks vs ipilimumab; p=0·0009 and 0·68, 0·53–0·86 for pembrolizumab every 3 weeks vs ipilimumab; p=0·0008). 24-month overall survival rate was 55% in the 2-week group, 55% in the 3-week group, and 43% in the ipilimumab group.

Interpretation

Substantiating the results of the interim analyses of KEYNOTE-006, pembrolizumab continued to provide superior overall survival versus ipilimumab, with no difference between pembrolizumab dosing schedules. These conclusions further support the use of pembrolizumab as a standard of care for advanced melanoma.

Funding

Merck & Co.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
猕猴桃完成签到,获得积分10
3秒前
饱满飞绿完成签到,获得积分10
9秒前
Jasper的应助被狗熊岭在逃翠花采纳,获得10
10秒前
年鱼精完成签到 ,获得积分10
12秒前
脑洞疼的应助被听话的含羞草采纳,获得10
16秒前
Hello的应助被soilman采纳,获得10
23秒前
尊敬怀柔完成签到 ,获得积分10
24秒前
隐形曼青的应助被April采纳,获得10
28秒前
有魅力初夏完成签到,获得积分10
29秒前
怡然晓兰完成签到 ,获得积分10
32秒前
34秒前
旺仔仔完成签到,获得积分10
34秒前
兮陌完成签到 ,获得积分10
40秒前
April发布了新的文献求助10
40秒前
玲玲完成签到,获得积分10
41秒前
危机的觅风完成签到,获得积分10
42秒前
44秒前
soilman发布了新的文献求助10
47秒前
flora完成签到 ,获得积分10
52秒前
优秀函完成签到,获得积分10
1分钟前
小巧慕儿完成签到,获得积分10
1分钟前
1分钟前
1分钟前
claire完成签到 ,获得积分10
1分钟前
平常香发布了新的文献求助10
1分钟前
玲玲发布了新的文献求助10
1分钟前
meng完成签到 ,获得积分10
1分钟前
1分钟前
Maestro_S的应助被平常香采纳,获得10
1分钟前
仰勒完成签到 ,获得积分10
1分钟前
科目三的应助被Lonely采纳,获得10
1分钟前
leo123发布了新的文献求助10
1分钟前
美满的夏山完成签到 ,获得积分10
1分钟前
SciGPT的应助被soilman采纳,获得10
1分钟前
复杂的雁芙完成签到,获得积分10
1分钟前
1分钟前
1分钟前
soilman发布了新的文献求助10
1分钟前
时之王者发布了新的文献求助10
1分钟前
TwentyNine完成签到 ,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185091
求助须知:如何正确求助?哪些是违规求助? 9574009
关于积分的说明 21833941
捐赠科研通 7782532
什么是DOI,文献DOI怎么找? 3434500
关于科研通互助平台的介绍 2558701
邀请新用户注册赠送积分活动 2481201